摘要
目的 观察卡铂、足叶乙甙 (CE方案 )联合放射同步治疗局限期小细胞肺癌的临床疗效。方法 局限期小细胞肺癌患者 90例 ,采用信封抽签随机分组进入同步治疗组 (A组 )和序贯治疗组 (B组 )。两组患者均接受CE方案治疗 6个周期和放射治疗 (简称放疗 ) 6周 (剂量为 6 0Gy)。A组患者化学治疗 (化疗 )与放疗同时进行 ;B组先给予 4个周期化疗 ,再进行放疗 ,然后再化疗 2个周期。结果 A组患者中位生存时间 2 6个月 ,5年生存率 2 7% ;B组患者中位生存时间 19个月 ,5年生存率 16 % ,两组差异有显著性 ( χ2 =4 10 4 ,P <0 0 5 )。两组患者主要毒副反应为骨髓抑制 ,Ⅲ、Ⅳ度白细胞下降发生率A组为 93 3% ( 4 2 / 4 5 ) ,B组为 75 5 % ( 34/ 4 5 ) ,差异有显著性 ( χ2 =5 4 13,P <0 0 5 )。结论 CE方案联合放射同步治疗 。
Objective To observe the effect of concurrent radiotherapy combined with carboplatin and etoposide in limited stage small cell lung cancer. Methods Ninety patients with limited stage small cell lung cancer were randomized into two groups, concurrent treatment group(group A) and sequential treatment group(group B) All the patients in two groups received radiotherapy (60 Gy in 6 weeks) and six courses of chemotherapy(carboplatin and etoposide) Radiotherapy was started in the first course of chemotherapy in group A Patients of group B were treated by radiation between the fourth and the fifth course of chemotherapy Results The median survival time was 26 months in group A and 19 months in group B The 5 year survival rate was 27% in group A and 16% in group B The major toxic reactions were grade Ⅲ Ⅳ myelosuppression The differences of two groups were significant( P <0 05) Conclusion Concurrent radiotherapy combined with carboplatin and etoposide can significantly improve median survival time and 5 year survival rate of patients with limited stage small cell lung cancer
出处
《中华结核和呼吸杂志》
CAS
CSCD
北大核心
2004年第4期237-239,共3页
Chinese Journal of Tuberculosis and Respiratory Diseases
